MAM and LDL receptor class A domain containing 1Genealiases: C10orf112 · DIET1 · bA265G8.2
Q-omics provides the consensus-scored MALRD1 profile across patient tissues and cancer cell-line models. MALRD1 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, MALRD1 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, MALRD1 RNA expression shows 13,150 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight BLCA, KIRC, and TGCT as cancer lineages where MALRD1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MALRD1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MALRD1 survival associations across molecular data types. MALRD1 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MALRD1 RNA expression–survival associations across cancer types. High MALRD1 expression shows unfavorable associations in BLCA, COAD, LGG and KIRP, but favorable associations in LUAD and BRCA. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for MALRD1 RNA expression.
This table summarizes MALRD1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for MALRD1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MALRD1 shows lower tumor expression in KIRC, KIRP, LUSC, UCEC and KICH and higher tumor expression in BRCA. The KIRC box plot shows higher MALRD1 RNA expression in normal versus tumor tissue (log2 FC = −0.555, t-test p < 0.001).
This table shows molecular features associated with MALRD1 in patient tissues and cancer cell lines. In patient samples, MALRD1 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, MALRD1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE.
